Lyka Labs Share Price Target (2025–2030) Lyka Labs Ltd is a pharmaceutical company specializing in the development. Manufacturing, and marketing of a broad range of pharmaceutical products. Including injectables, topical formulations, and specialty medicines. As of January 9, 2025, the share price of Lyka Labs on the NSE is ₹148.61 INR. Below are further details regarding the share price targets, market performance, and financial outlook.
Lyka Labs Ltd Market Overview
| Parameter | Value |
| Open Price | ₹157.88 |
| High Price | ₹158.23 |
| Low Price | ₹146.50 |
| Previous Close | ₹157.71 |
| Volume | 110,556 |
| Value (Lacs) | ₹163.49 |
| VWAP | ₹150.91 |
| UC Limit | ₹189.25 |
| LC Limit | ₹126.16 |
| 52 Week High | ₹176.59 |
| 52 Week Low | ₹97.90 |
| Market Capitalization | ₹489 Crore |
| Face Value | ₹10 |
Lyka Labs Share Price Target Tomorrow 2025 To 2030
Lyka Labs Share Price Target Tomorrow 2025 ₹180, 2026 ₹205, 2027 ₹230, 2028 ₹270, 2029 ₹300 To 2030 ₹330
Lyka Labs Share Price Target 2025–2030
| Year | Share Price Target (INR) |
| 2025 | ₹180 |
| 2026 | ₹205 |
| 2027 | ₹230 |
| 2028 | ₹270 |
| 2029 | ₹300 |
| 2030 | ₹330 |
| Category | Stock Market |
Lyka Labs Share Price Target 2025
The expected target for 2025 is ₹180. Key factors influencing this target include:
- New Product Launches: Introducing innovative pharmaceutical products, especially in niche therapeutic areas. Can significantly drive revenue and increase investor confidence.
- Regulatory Approvals: Achieving product approvals in highly regulated markets such as the US and Europe can open up new growth opportunities and expand market reach.
- Expansion in Export Markets: Expanding exports to semi-regulated and emerging markets could greatly contribute to revenue growth due to rising demand for generics and specialty medicines.
- Strategic Collaborations: Forming partnerships with global pharmaceutical companies for. Manufacturing or marketing can enhance operational efficiency and improve visibility in international markets.
Lyka Labs Share Price Target 2030
The expected target for 2030 is ₹330. However, the company faces several risks and challenges:
- Regulatory Hurdles: Stringent compliance requirements in markets like the US FDA and EU regulations could lead to delays in product approvals, impacting revenue.
- Competitive Pressure: Increased competition from both domestic and international pharmaceutical companies may result in pricing pressure and a reduction in market share. Especially for generic medicines.
- R&D and Innovation Risks: Delays in developing innovative products or failure to launch new drugs could impact growth and profitability in the long term.
- Macroeconomic and Currency Risks: Fluctuations in foreign exchange rates and adverse economic conditions in key export markets could negatively affect earnings and financial stability.
Also Read: Zuari Industries Share Price Target Tomorrow 2025 To 2030
Lyka Labs Ltd Shareholding Pattern
| Shareholder | Percentage |
| Promoters | 58.10% |
| Retail and Others | 41.08% |
| DII | 0.66% |
| FII | 0.15% |
| Mutual Funds | 0.01% |
Lyka Labs Ltd Financials
| Financials | Amount (INR) | Y/Y Change |
| Revenue | ₹1.06 Billion | +18.75% |
| Operating Expenses | ₹567.24 Million | +19.65% |
| Net Income | -₹24.89 Million | +81.16% |
| Net Profit Margin | -2.34% | +84.17% |
| Earnings per Share | — | — |
| EBITDA | ₹135.72 Million | -19.67% |
| Effective Tax Rate | -180.61% | — |
Lyka Labs faced challenges with profitability as reflected in the negative net income and EBITDA. However, the company showed a substantial improvement in net profit margin compared to the previous year. The company’s focus on regulatory approvals, new product launches. And international market expansion will be crucial to its financial recovery and future growth.
Who is the owner of Lyka Labs?
Kunal Narendra Gandhi, Lyka Labs Ltd: Profile and Biography – Bloomberg Markets.
Who is the CFO of Lyka Labs?
Yogesh B. Shah
Yogesh B. Shah, Commerce Graduate, has more than 30 years of experience in Accounting and Finance field. He has been appointed as a Chief Financial Officer of the Company since July, 2014.
What is the address of Lyka Labs?
Corporate Address
Lyka Labs Ltd. Spencer Building, ( Block B & C ),30, Forjett Street, Near Bhatia Hospital,Grant Road (West), Mumbai – 400007 INDIA .
How much stake IPCA has in Lyka Labs?
For Ipca Laboratories Limited With this allotment, the Company’s shareholding in Lyka Labs Ltd. now is 1,46,24,923 equity shares of Rs. 10/- each representing 40.98% of its paid-up equity share capital from 36.34% held by us prior to this allotment.